Applied Biosystems Introduces the Life Science Industry's Fastest Real-Time PCR Genotyping Solution.

TaqMan([R]) Sample-to-SNP([TM]) Reagents Enable Researchers to Obtain Genotyping Results From a Wide Variety of Biological Samples in Less Than One Hour

FOSTER CITY, Calif. -- Applied Biosystems Inc. (NYSE:ABI) today announced the worldwide availability of a new universal genotyping reagent solution that accelerates the generation of high-quality genotyping data for a host of life science applications. The TaqMan([R]) Sample-to-SNP([TM]) Kit enables scientists who conduct genetic disease investigations, cancer research, transgenic animal studies, plant research, and agricultural seed selection to prepare a wide variety of biological samples for real-time PCR in minutes and generate accurate genotypes for those samples in less than one hour.

The TaqMan([R]) Sample-to-SNP([TM]) Kit provides researchers with a sample preparation protocol that significantly advances the way they conduct their genotyping experiments by enabling them to rapidly perform studies that analyze genetic variations such as single nucleotide polymorphisms (SNPs). Through the development of this new kit, Applied Biosystems has eliminated the need for scientists to create unique processing procedures - such as DNA purification - for different sample types, which is typically time-consuming, ranging from a few hours to several days, depending upon the experiment.

At the University of Texas at Austin, for instance, researchers are accelerating SNP genotyping workflows by using the new TaqMan Sample-to-SNP Kit in breeding experiments to identify rare recombinant plants. They are studying how genetic variation in the model angiosperm, Arabidopsis thaliana, allows some plants to escape, avoid, or tolerate drought stress. A better understanding of how plants have solved this problem in nature will help the researchers in their efforts to develop better crops through breeding and genetic engineering. They have found that the reagents can convert leaf samples to genotypes without the need for separate DNA purification procedures. They also only need a small amount of leaf sample and a minimal number of assays to rapidly generate genotypes for a large number of plant samples.

"With the TaqMan Sample-to-SNP Kit, we can use a smaller amount of leaf tissue for our experiments, greatly reducing the time needed to get high-quality SNP genotyping data, and making it possible for us to harvest plants earlier," said Tom Juenger, Ph.D., an associate professor in the university's Section of Integrative Biology. "By using these new reagents, we can avoid costly DNA purification procedures allowing us to grow greater numbers of plants in each generation, while significantly reducing the possibility of cross-sample contamination."

The TaqMan Sample-to-SNP Kit consists of two primary components: the sample-preparation component, namely DNA Extract All Lysis Reagents, which consist of chemical lysis, and DNA-stabilization reagents; and the fast genotyping component, which is the TaqMan([R]) GTXpress(TM) Master Mix. This kit enables researchers to release DNA from biological samples that include blood, cells, buccal swabs, mouse tails, plant leaves, seeds, or formalin-fixed, paraffin-embedded (FFPE) tissues, often used to archive cancerous tissue specimens. PCR reactions for genotyping analysis can be performed with one of Applied Biosystems' real-time PCR, or fast real-time PCR systems.

"By introducing the fastest, most versatile set of TaqMan genotyping reagents we've ever developed, Applied Biosystems continues to strengthen its growing portfolio of genotyping solutions," said Peter Dansky, president for Applied Biosystems' functional analysis division. "Providing researchers with a single reagent kit, which can generate high-quality data from almost any biological sample within an hour, will simplify and accelerate genotyping projects that range from disease research to agricultural applications."

Applied Biosystems offers one of the life-science industry's most comprehensive lines of genotyping and RNA expression analysis solutions that include individual TaqMan assays and arrays of assays for microRNA analysis, along with a complete line of TaqMan([R]) Array gene signature panels. With over 4.5 million TaqMan([R]) SNP Genotyping Assays, TaqMan DME Genotyping Assays, 1 million TaqMan([R]) Gene Expression Assays, custom assays, and industry-leading reagents and instruments, Applied Biosystems is a leading provider of fast, simple and effective genotyping and gene expression tools.

For more information about the TaqMan Sample-to-SNP Kit see http://info.appliedbiosystems.com/sample2snp.

About Applied Biosystems Inc.

Applied Biosystems Inc. (formerly known as Applera Corporation) is a global leader in the development and marketing of instrument-based systems, consumables, software, and services for academic research, the life science industry and commercial markets. Driven by its employees' belief in the power of science to improve the human condition, the company commercializes innovative technology solutions for DNA, RNA, protein and small molecule analysis. Customers across the disciplines of academic and clinical research, pharmaceutical research and manufacturing, forensic DNA analysis, and agricultural biotechnology use the company's tools and services to accelerate scientific discovery, improve processes related to drug discovery and development, detect potentially pathogenic microorganisms, and identify individuals based on DNA sources. Applied Biosystems has a comprehensive service and field applications support team for a global installed base of high-performance genetic and protein analysis solutions. Applied Biosystems Inc. is headquartered in Norwalk, CT. On June 12, 2008, Applera Corporation and Invitrogen Corporation (NASDAQ: IVGN) announced that their Boards of Directors had approved a definitive merger agreement under which Invitrogen will acquire all of the outstanding shares of Applied Biosystems stock. The merger is subject to customary closing conditions and is targeted to close in mid-November 2008, subject to stockholder approvals and receipt of antitrust clearance under the European Council Merger Regulation. Further information regarding the merger has been provided in a joint proxy statement/prospectus mailed to stockholders of the company and Invitrogen. Investors and security holders are urged to read this document because it contains important information. Information about Applied Biosystems, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.appliedbiosystems.com.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should, "planned," and "expect," among others. These forward-looking statements are based on our current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, we note that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in our filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and we do not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures. Practice of the patented 5' Nuclease Process requires a license from Applied Biosystems. The purchase of the TaqMan Array Human MicroArray Panel includes an immunity from suit under patents specified in the product insert to use only the amount purchased for the purchaser's own internal research when used with the separate purchase of an Authorized 5' Nuclease Core Kit. No other patent rights are conveyed expressly, by implication, or by estoppel. For further information on purchasing licenses contact the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA. The TaqMan[R] Low Density Array is covered by U.S. Patents Nos. 6,514,750 and 6,942,837. Micro Fluidic Card developed in collaboration with 3M Company.

[c]Copyright 2008. Applied Biosystems Inc. All rights reserved. Applied Biosystems, and AB (Design) are registered trademarks and Sample-to-SNP, and GTXpress are trademarks of Applied Biosystems Inc. or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc. All other trademarks are trademarks of their respective owners.